Tags · Evidence

randomised trial

Randomised controlled trial evidence.

174 topics 62 solved Group: Evidence

174 topics · page 2 of 6

Topic	Participants	Replies	Views	Activity
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…	+5	9	30k	8d
[2026 update] Journal club: FLOW and the renal composite, component by component Evidence › Journal club journal club randomised trial estimand Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	21k	9d
Tirzepatide storage and stability: what is published versus what is assumed Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…	+17	21	17k	12d
Interim analyses and stopping rules Evidence › Trials intention to treat surrogate endpoints open label discontinuation & dropout Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do not think…	+25	29	35k	16d
Why fasting instructions for oral semaglutide are not optional advice Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Solved Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…	+70	74	1.1k	23d
Why oral semaglutide needs an absorption enhancer at all — one year on Compounds › Oral incretins randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…	+11	15	17k	24d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+27	31	17k	25d
Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…	+5	9	13k	25d
Journal club: STEP 3 and the intensive behavioural therapy floor Evidence › Journal club randomised trial journal club effect size risk of bias Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…	+6	10	13k	28d
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+62	68	2.6k	29d
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide effect size type 2 diabetes semaglutide STEP programme Solved The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…	+23	27	9.9k	1mo
Run-in periods and the population they select Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…	+130	142	7.3k	1mo
Journal club: SELECT, absolute risk, and how it was reported Evidence › Journal club journal club estimand randomised trial effect size Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read…		2	52k	1mo
Journal club: SELECT, absolute risk, and how it was reported — a second dataset Evidence › Journal club risk of bias effect size randomised trial journal club On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…		4	1.3k	1mo
Reading a trial's population section before its results Evidence › Trials estimand surrogate endpoints discontinuation & dropout randomised trial Solved On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+91	109	22k	2mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…	+109	122	3.6k	2mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…	+3	7	1k	2mo
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
Subgroup analyses: pre-specified versus discovered — a second dataset Evidence › Trials open label discontinuation & dropout estimand randomised trial On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet ,…	+71	79	906	3mo
Primary endpoint hierarchies and why order matters Evidence › Trials randomised trial intention to treat estimand Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with SURPASS-2 ( N Engl J…		4	308	3mo
Journal club: is percentage weight change the right endpoint? Evidence › Journal club number needed to treat randomised trial journal club Solved Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-OSA (…	+116	120	23k	3mo
Follow-up: What a statistical analysis plan adds that the paper does not Evidence › Trials randomised trial estimand open label surrogate endpoints What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	7.2k	3mo
Open-label extensions: what survives and what does not Evidence › Trials discontinuation & dropout randomised trial estimand Closed Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with PIONEER 6 ( N Engl J Med ,…		4	22k	3mo
Oral semaglutide bioavailability and its variability between people Compounds › Oral incretins SOUL trial oral semaglutide randomised trial Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…	+44	48	574	3mo
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide effect size randomised trial SELECT trial On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…	+41	46	1.2k	4mo
Run-in periods and the population they select — the long version Evidence › Trials randomised trial estimand intention to treat surrogate endpoints Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please read…		2	8.9k	4mo
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…	+73	79	2k	4mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…	+128	145	3k	4mo
The most common factual error about semaglutide on the internet — what changed since Compounds › Semaglutide effect size randomised trial SELECT trial type 2 diabetes The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…	+42	46	1.7k	5mo
Journal club: PIONEER 6 as a safety trial Evidence › Journal club effect size journal club number needed to treat risk of bias Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it before posting; the…	+14	18	262	5mo